Jennifer Bush, Chief Operating Officer, Chief Legal Officer, and Compliance Officer of Artiva Biotherapeutics, Inc., filed a Form 4 on September 4, 2026, reporting a sale of common stock on September 3, 2026, executed automatically under the company's sell-to-cover policy to satisfy tax withholding obligations.

Key Highlights

  • Reporting person: Jennifer Bush, serving as COO, CLO, and Compliance Officer of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
  • Shares sold: 8,391 shares of common stock disposed of on September 3, 2026, with transaction code S
  • Weighted average price: $11.1555 per share, with individual sale prices ranging between $11.0350 and $11.1556
  • Purpose of sale: According to the filing, shares were sold automatically under the issuer's sell-to-cover policy to cover tax withholding obligations connected to the vesting and release of restricted stock units
  • Beneficial ownership after transaction: 329,529 shares of common stock held directly following the reported transaction

Artiva Biotherapeutics Executive Share Sale Tied to RSU Vesting

According to the Form 4 filed with the SEC, Jennifer Bush disposed of 8,391 shares of Artiva Biotherapeutics common stock on September 3, 2026. The filing identifies Bush's roles as COO, CLO, and Compliance Officer. The transaction carries code S, indicating a sale on the open market, and was reported as a direct ownership transaction.

The filing states that the sale was not discretionary. As disclosed, "the Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person," and the shares sold represent the number required to cover those obligations in connection with the vesting and release of restricted stock units. The filing further notes that such sales "were automatic and not at the discretion of the Reporting Person."

The weighted average sale price was reported as $11.1555, with individual transaction prices falling between $11.0350 and $11.1556. The filing states that full detail on the number of shares sold at each separate price is available upon request by the SEC staff, the issuer, or any security holder. Following the transaction, Bush's direct beneficial ownership stands at 329,529 shares of common stock, according to the filing.

What Was Disclosed

The filing reports an automatic sell-to-cover disposal of 8,391 shares by Artiva Biotherapeutics officer Jennifer Bush on September 3, 2026, at a weighted average price of $11.1555, leaving her with 329,529 shares held directly.